Endothelial dysfunction potentially interacts with impaired glucose metabolism to increase cardiovascular risk

Hypertension

Volumn 64, Issue 6, 2014, Pages 1192-1193

  Jia, Guanghong ^a,b   Sowers, James R ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Population; Type 2 diabetes mellitus

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ARGININE; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; INSULIN; INSULIN RECEPTOR SUBSTRATE; INTERCELLULAR ADHESION MOLECULE 1; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITIDE 3 KINASE; PHOSPHOTRANSFERASE; PROSTACYCLIN; PROTEIN KINASE B; RAMIPRIL; ROSIGLITAZONE; S6 KINASE; THROMBOXANE A2; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

CARDIOVASCULAR RISK; CELL COUNT; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; FUNCTIONAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPEREMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIMB ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OXIDATIVE STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VASCULAR SMOOTH MUSCLE; VASODILATATION; CARDIOVASCULAR DISEASE; COMPLICATION; FEMALE; HEALTH SURVEY; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; POPULATION SURVEILLANCE; VASCULAR RESISTANCE; VASODILATION;

EID: 84922481654     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04348     Document Type: Note

References (10)

1. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR; DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-1562.
2. Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013;61:943-947.
3. Frankel DS, Meigs JB, Massaro JM, Wilson PW, O'Donnell CJ, D'Agostino RB, Tofler GH. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation. 2008;118:2533-2539.
4. Song Y, Manson JE, Tinker L, Rifai N, Cook NR, Hu FB, Hotamisligil GS, Ridker PM, Rodriguez BL, Margolis KL, Oberman A, Liu S. Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes. 2007;56:1898-1904.
5. Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab. 2012;302:E201-E208.
6. Jia G, Aroor AR, Whaley-Connell AT, Sowers JR. Fructose and uric acid: is there a role in endothelial function? Curr Hypertens Rep. 2014;16:434.
7. De Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Endothelial dysfunction and low-grade infammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol. 2006;26:1086-1093.
8. Van Sloten TT, Henry RMA, Dekker JM, Nijpels G, Unger T, Schram MT, Stehouwer CDA. Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn Study. Hypertension. 2014;64:1299-1305.
9. Poredos P, Jezovnik MK. Testing endothelial function and its clinical relevance. J Atheroscler Thromb. 2013;20:1-8.
10. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Lüscher TF, Shechter M, Taddei S, Vita JA, Lerman A. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126:753-767.